Incyte

Yahoo Finance • 3 hours ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1.3% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 hours ago

Sector Update: Health Care Stocks Higher Friday Afternoon

Health care stocks rose Friday afternoon, with the NYSE Health Care Index and the State Street Healt PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 11 hours ago

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeks The study is the first and largest of its kind speci... Full story

Yahoo Finance • 8 days ago

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as... Full story

Yahoo Finance • 8 days ago

Where is Incyte Corporation (INCY) Headed According to Analysts?

Incyte Corporation (NASDAQ:INCY) is one of the best immunotherapy stocks to buy according to hedge funds. Jefferies reiterated a Buy rating on Incyte Corporation (NASDAQ:INCY) on February 11, setting a price target of $120. The same day, M... Full story

Yahoo Finance • 16 days ago

Pharma companies left out of Trump's drug-pricing deals look for way in

By Michael Erman SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U.S. drug pricing are looking to craft their own deals in an attempt to avoid potentiall... Full story

Yahoo Finance • 17 days ago

Stocks are Mixed After Weak Retail Sales Data Released

The S&P 500 Index ($SPX) (SPY) today is down -.10%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.12%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.25%. Stock indexes are mixed today. This morning a weaker-than-expected repo... Full story

Yahoo Finance • 17 days ago

Stocks Climb on Fed Rate Cut Hopes

The S&P 500 Index ($SPX) (SPY) today is up +0.18%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.46%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.15%.  March E-mini S&P futures (ESH26) are up +0.17%, and March E-mini Nasdaq fu... Full story

Yahoo Finance • 17 days ago

Stocks making the biggest moves midday: Ferrari, Incyte, S&P Global, Datadog, BP and more

Check out some of the companies making the biggest moves midday: Amentum Holdings — The defense contractor tumbled about 12% after fiscal first-quarter revenue and adjusted EBITDA missed Wall Street analysts' consensus estimates, according... Full story

Yahoo Finance • 17 days ago

Incyte weak 2026 revenue forecast heightens Jakafi patent concerns

Feb 10 (Reuters) - Incyte forecast annual sales below Wall Street estimates on Tuesday with its key growth driver Opzelura expected ​to underperform, raising concerns about the drugmaker's ability to offset ‌looming patent losses on top-se... Full story

Yahoo Finance • 17 days ago

Incyte Reports Fourth Quarter and Full Year 2025 Financial Results

Total revenue of $1.51 billion (+28% Y/Y) in the fourth quarter 2025 and $5.14 billion (+21% Y/Y) for the full year 2025 Total net product revenue of $1.22 billion (+20% Y/Y) in the fourth quarter 2025 and $4.35 billion (+20%) for the ful... Full story

Yahoo Finance • 18 days ago

Here are the major earnings before the open Tuesday

Major earnings expected before the bell on Tuesday include: * The Coca-Cola Company (KO [https://seekingalpha.com/symbol/KO]) * CVS Health Corporation (CVS [https://seekingalpha.com/symbol/CVS]) * BP p.l.c. (BP [https://seekingalpha... Full story

Yahoo Finance • 18 days ago

From Gold to Chips: Large-Cap names with the most days at bullish Quant ratings

[Powerful Bull Symbolizing Stock Market Growth] Silver Place In a 2026 market defined by selective risk-taking and a renewed focus on quality and durability of earnings, we look at a list of the top 10 large cap stocks ranked by the highe... Full story

Yahoo Finance • 22 days ago

Microsoft downgraded, Snap upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: B. Riley upgraded Snap (SNAP) to Buy fro... Full story

Yahoo Finance • 23 days ago

TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029

Incyte Corporation (NASDAQ:INCY) is one of the most undervalued quality stocks to buy right now. On January 13, TD Cowen raised its price target for Incyte to $128 from $101 with a Buy rating on the shares. The firm’s optimism follows Incy... Full story

Yahoo Finance • 25 days ago

Analysts Differ in Opinion on Jakafi Drug Maker Incyte (INCY)

Incyte Corp (NASDAQ:INCY) is one of the most undervalued stocks to buy and hold for 5 years. On January 27, Bank of America Securities analyst Tazeen Ahmad assigned a Buy rating to Incyte and set a $118 price target. This bullish ratings a... Full story

Yahoo Finance • 2 months ago

Is It Too Late To Consider Incyte After A 45% Rally In 2025?

If you are wondering whether Incyte at around $100 a share is still good value or if the easy gains are behind it, you are not alone. This is exactly the question we are going to unpack. The stock is up 44.8% year to date and 44.2% over th... Full story

Yahoo Finance • 2 months ago

Incyte Japan gains approval for Minjuvi with rituximab and lenalidomide to treat relapsed follicular lymphoma

Incyte Biosciences Japan G.K. (INCY [https://seekingalpha.com/symbol/INCY]) on Monday reported [https://seekingalpha.com/pr/20346677-incyte-japan-announces-approval-of-minjuvi-tafasitamab-in-combination-with-rituximab-and] the approval fro... Full story

Yahoo Finance • 2 months ago

Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del., December 18, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST). The presentation will be w... Full story

Yahoo Finance • 2 months ago

Incyte's Minjuvi Gets Second Nod From EC For R/R Follicular Lymphoma

(RTTNews) - Incyte Corp. (INCY) announced on Thursday that the European Commission has approved Minjuvi in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL)... Full story